# Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)

> **NCT01986010** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 190 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** V160 Low Dose IM
- **BIOLOGICAL:** V160 Medium Dose IM
- **BIOLOGICAL:** V160 High Dose IM
- **BIOLOGICAL:** V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
- **BIOLOGICAL:** V160 High Dose plus MAPA 225 µg /dose IM
- **BIOLOGICAL:** V160 Maximum Dose IM
- **OTHER:** Placebo IM
- **BIOLOGICAL:** V160 Medium Dose ID
- **OTHER:** Placebo ID

## Key facts

- **NCT ID:** NCT01986010
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-25
- **Primary completion:** 2016-04-19
- **Final completion:** 2017-03-14
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2021-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986010, "Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT01986010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*